Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD

This study has been terminated.
(Management decision)
Information provided by (Responsible Party):
Alcon Research Identifier:
First received: July 31, 2003
Last updated: September 4, 2013
Last verified: May 2009
The purpose of this study is to investigate the long-term efficacy and safety of posterior juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.

Condition Intervention Phase
Macular Degeneration
Drug: Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label Evaluation of Long Term Efficacy and Safety of Posterior Juxtascleral Injections of Anecortave Acetate 15 mg in Patients With Subfoveal Exudative Age-Related Macular Degeneration (AMD)

Resource links provided by NLM:

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Percent of patients who maintained stable vision [ Time Frame: Month 24 ]
    Stable vision is defined as < 15-letter loss of best-corrected visual acuity scores)

  • Mean change in best-corrected visual acuity at Month 24 from baseline [ Time Frame: Baseline, Month 24 ]

Enrollment: 111
Study Start Date: June 2003
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Anecortave Acetate, 15 mg
One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months
Drug: Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL
One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with subfoveal exudative age-related macular degeneration (AMD) who were previously enrolled in long-term studies with anecortave acetate.
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

  • Other protocol-defined exclusion criteria may apply.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00065728

United States, Texas
Central Contact Ft. Worth, Texas, United States, 76134
Sponsors and Collaborators
Alcon Research
Study Director: Terry Wiernas, PhD Alcon Research
  More Information

Responsible Party: Alcon Research Identifier: NCT00065728     History of Changes
Other Study ID Numbers: C-03-15
Study First Received: July 31, 2003
Last Updated: September 4, 2013

Keywords provided by Alcon Research:
age-related macular degeneration
Wet form of age-related macular degeneration
Anecortave Acetate

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on May 25, 2017